%0 Journal Article
%T An expanding role for osimertinib for the treatment of ErbB family driven NSCLC
%A Faber, Anthony C.
%A Burns, Timothy F.
%J Translational Cancer Research
%D 2018
%B 2018
%9 
%! An expanding role for osimertinib for the treatment of ErbB family driven NSCLC
%K 
%X The discovery that a subset of non-small cell lung cancers (NSCLC) were dependent upon reoccurring activating EGFR (ErbB1) mutations (1-4), primarily deletions of  exon 19 or an activating point mutation, L858R, ushered in the era of targeted therapies for lung cancer.
%U https://tcr.amegroups.org/article/view/23518
%P S787-S791
%@ 2219-6803